JAC Advance Access originally published online on January 14, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 51, 213-217
© 2003 The British Society for Antimicrobial Chemotherapy
Leading Article |
Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART
HIV Research Department, Chelsea and Westminster Hospital, London, UK
Keywords: HIV, fusion inhibitor
| The first 150 words of the full text of this article appear below. |
 |
Introduction: current therapy obstacles |
|---|
HIV therapeutics has a number of unmet needs, most notably issues of resistance, toxicity and the requirement for chronic therapy. The management of individuals with virus resistant to multiple antiretroviral drug classes is a major challenge in clinical practice. Resistance to one or more approved drug classes may be a consequence of multiple regimen failures, but is increasingly seen in individuals who have recently acquired HIV. Studies of resistance testing indicate advantages, to both genotypic and phenotypic evaluations, over using treatment history alone, in optimizing drug choice for new regimens. However, success in resistance testing studies is also influenced by the availability of treatment options. In the Narval study,1 performed predominantly in individuals who had received multiple lines of antiretroviral therapy and commonly had virus resistant to all three approved drug classes, the advantages to resistance-optimized therapy that had been reported from the VIRADAPT, GART, VIRA3001 and Havana studies were
|
New drug targets |
|---|
|
Enfuvirtide: efficacy data |
|---|
|
Administration issues |
|---|
|
Resistance |
|---|
|
Clinical roles for enfuvirtide therapy |
|---|
|
Conclusions |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Stanic and T. K. Schneider Overview of Antiretroviral Agents in 2005 Journal of Pharmacy Practice, August 1, 2005; 18(4): 228 - 246. [Abstract] [PDF]
|
|
|
|
 |
|
 M. L. Greenberg and N. Cammack Resistance to enfuvirtide, the first HIV fusion inhibitor J. Antimicrob. Chemother., August 1, 2004; 54(2): 333 - 340. [Abstract] [Full Text] [PDF]
|
|